تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Waters Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $41.7B | |
|---|---|---|
| Revenue (ttm) | 4.6B | |
| Net income (ttm) | 166.6M | |
| EPS (ttm) | $2.21 | |
| Shares out | 98.2M | |
| P/E (trailing) | 215.3x | |
| P/E (forward) | 24.8x | |
| Volume | 722,879 | |
| Beta | 1.15 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.79B | $2.97B | $2.96B | $2.96B | $3.17B | +3.2% |
| Gross profit | $1.63B | $1.72B | $1.76B | $1.76B | $1.83B | +2.9% |
| Operating income | $821.7M | $873.4M | $817.7M | $826.4M | $802.6M | -0.6% |
| Net income | $692.8M | $707.8M | $642.2M | $637.8M | $642.6M | -1.9% |
| EPS (diluted) | $11.17 | $11.73 | $10.84 | $10.71 | $10.76 | -0.9% |
| EBITDA | $982.8M | $1.02B | $817.7M | $1.04B | $1.01B | +0.7% |
| R&D | $168.4M | $176.2M | $174.9M | $183.0M | $195.7M | +3.8% |
| SG&A | $627.0M | $658.0M | $736.0M | $690.1M | $830.4M | +7.3% |
Recent company headlines from major financial publishers.
Under the modal base path, Waters delivers steady compound growth anchored by recurring chemistry consumables ($631.46M in FY2025) and service revenues ($1,188.19M). Top-line revenue expands from $6,466.84M in FY2026 to $7,136.40M in FY2027, while operating margins improve gradually toward long-term targets by FY2030 supported by 90 bps of pricing realization. Disciplined capital allocation and share buybacks offsetting SBC support diluted EPS progression from $14.58 in FY2026 to $16.54 in FY2027, yielding a synthesized fair value midpoint of $345.34.
Under the upside trajectory, biopharmaceutical R&D and lab capital expenditure rebound sharply across North America and Europe, accelerating replacement across the 12,000-unit installed base. Expanding GLP-1 testing volumes and reagent rental compliance across 700 accounts lift pricing realization to 150 bps, while biopharma reshoring drives incremental lab placements through 2030. Operating margins expand toward 28-30%, supporting compound diluted EPS growth above consensus expectations toward the upper fair value boundary ($440.18).
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 8.6% | $340 | $346 | $352 | $359 | $367 |
| 9.1% | $324 | $329 | $334 | $339 | $346 |
| 9.6% | $310 | $314 | $345 | $323 | $328 |
| 10.1% | $298 | $301 | $304 | $308 | $313 |
| 10.6% | $287 | $289 | $293 | $296 | $299 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
